JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258775

Human ACAD9 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ACAD9 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

View Alternative Names

ACAD9_HUMAN, Acyl CoA dehydrogenase 9, Acyl Coenzyme A dehydrogenase family, member 9, Acyl-CoA dehydrogenase family member 9, FLJ23533, MGC14452, NPD002, Very long chain acyl CoA dehydrogenase VLCAD, acyl-CoA dehydrogenase family member 9, mitochondrial, mitochondrial

1 Images
Sanger Sequencing - Human ACAD9 knockout HeLa cell lysate (AB258775)
  • Sanger seq

Unknown

Sanger Sequencing - Human ACAD9 knockout HeLa cell lysate (AB258775)

Homozygous : 1 bp insertion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258775-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ACAD9 knockout HeLa cell lysate", "number":"AB258775-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
ACAD9
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein ACAD9 also known as acyl-CoA dehydrogenase family member 9 plays a role in mitochondrial fatty acid β-oxidation. It functions as an enzyme that catalyzes the initial step of this fatty acid metabolism process assisting in breaking down long-chain fatty acids. The mass of ACAD9 is approximately 71 kDa. This protein mainly expresses in tissues with high energy demands such as heart and skeletal muscle indicating its involvement in energy metabolism.
Biological function summary

ACAD9 participates in key enzymatic activities important for energy production. It forms part of a larger enzyme complex known as the electron transfer flavoprotein (ETF)-ubiquinone oxidoreductase complex which is essential for the transfer of electrons in the mitochondrial respiratory chain. This protein aids in converting stored fatty acids into acetyl-CoA which is then funneled into the Krebs cycle for further energy generation.

Pathways

ACAD9 is intricately linked to mitochondrial fatty acid oxidation and energy metabolism. It plays a central role in the β-oxidation pathway which is critical for converting fatty acids into usable energy. ACAD9 interacts with related proteins such as electron transfer flavoprotein (ETF) and ETF-ubiquinone oxidoreductase facilitating the transfer of electrons derived from fatty acid metabolism into the respiratory chain thereby producing ATP efficiently.

Mutations or deficiencies in ACAD9 can lead to fatty acid oxidation disorders such as multiple acyl-CoA dehydrogenase deficiency. These conditions manifest with severe metabolic myopathies and cardiomyopathies. ACAD9's role connects it to other proteins involved in mitochondrial function such as ETF which also associates with similar disorders. Understanding ACAD9's function aids in diagnosing and developing therapeutic approaches for these metabolic conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com